$4.92 Billion is the total value of Avidity Partners Management LP's 98 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NKTX | NKARTA INC | $18,609,000 | +6.8% | 1,414,082 | 0.0% | 0.38% | -5.5% | |
| ATEC | ALPHATEC HLDGS INC | $14,989,000 | +33.6% | 1,715,000 | 0.0% | 0.30% | +18.7% | |
| SPNE | SEASPINE HLDGS CORP | $11,417,000 | +0.5% | 2,010,000 | 0.0% | 0.23% | -11.1% | |
| CMAX | CAREMAX INC | $5,355,000 | +95.3% | 755,329 | 0.0% | 0.11% | +73.0% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $5,148,000 | +1.2% | 520,000 | 0.0% | 0.10% | -10.3% | |
| BLSA | BCLS ACQUISITION CORP | $5,010,000 | +1.2% | 500,000 | 0.0% | 0.10% | -10.5% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $4,955,000 | +1.0% | 500,000 | 0.0% | 0.10% | -10.6% | |
| PANA | PANACEA ACQUISITION CORP II | $4,900,000 | +0.4% | 500,000 | 0.0% | 0.10% | -10.7% | |
| CMPX | COMPASS THERAPEUTICS INC | $4,560,000 | -14.0% | 2,000,000 | 0.0% | 0.09% | -23.8% | |
| EPIX | ESSA PHARMA INC | $4,477,000 | -42.2% | 2,460,000 | 0.0% | 0.09% | -48.9% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $3,960,000 | -0.6% | 400,000 | 0.0% | 0.08% | -11.0% | |
| DNAB | SOCIAL CAP SUVRETTA HLDS CRP | $1,960,000 | +0.8% | 200,000 | 0.0% | 0.04% | -11.1% | |
| DNAD | SOCIAL CAP SUVRETTA HLDS CP | $1,964,000 | +1.1% | 200,000 | 0.0% | 0.04% | -11.1% | |
| ONCS | ONCOSEC MED INC | $1,437,000 | -34.2% | 2,945,000 | 0.0% | 0.03% | -42.0% | |
| HYPERFINE INC | $1,218,000 | -63.7% | 1,503,754 | 0.0% | 0.02% | -67.5% | ||
| SEMA4 HOLDINGS CORP | $834,000 | -30.3% | 950,000 | 0.0% | 0.02% | -37.0% | ||
| SCIENCE 37 HOLDINGS INC | $692,000 | -19.9% | 430,000 | 0.0% | 0.01% | -30.0% | ||
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $18,000 | -35.7% | 99,999 | 0.0% | 0.00% | -100.0% | |
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $1,000 | -90.0% | 57,770 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.